Brief: Kiromic Reports Significant Progression Free Survival Benefit In Metastatic Pancreatic Cancer Patient Treated With KiroVax/BSK01
25/10/2021 12:10
Oct 25 (Reuters) - Kiromic Biopharma Inc KRBP.O :
* KIROMIC BIOPHARMA, NOW CLINICAL STAGE, REPORTS SIGNIFICANT
PROGRESSION FREE SURVIVAL BENEFIT IN METASTATIC PANCREATIC
CANCER PATIENT TREATED WITH KIROVAX/BSK01, COMPANY’S PHASE 1
CELL THERAPY CANCER VACCINE CANDIDATE FOR SOLID TUMORS
* KIROMIC BIOPHARMA - PROGRESSION FREE SURVIVAL OF 7 MONTHS
AFTER
TREATMENT WITH KIROVAX/BSK01 AND CHEMOTHERAPY VERSUS 3.9 MONTHS
WITH STANDARD OF CARE
Source text for Eikon: ID:nBw5n4wZVa
Further company coverage: KRBP.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Kiromic Biopharma
See all newsBrief: Kiromic Biopharma Files For Offering Up To 1 Million Units
Brief: Kiromic Biopharma Applies To List Common Stock On The NYSE American Under Symbol 'KRBP'
Brief: Kiromic Biopharma Advances Deltacel-01 Into Expansion Phase Following Safety Monitoring Committee's Unanimous Recommendation
Brief: Kiromic Biopharma Reports Favorable Results At Six Weeks From Fourth Patient In Deltacel-01 Clinical Trial
Brief: Kiromic BioPharma Adds UPMC as Fourth Deltacel-01 Clinical Trial Site